Pfizer and Alex Therapeutics announce a Strategic Commercial Partnership to provide evidence-based Digital Therapeutics to patients, starting in Germany
STOCKHOLM,Jan. 31,2022 -- The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world leading pharmaceutical company Pfizer have joined forces to provide evidence based,clinically validated and personalized digital therapies to patients. Together,the companies cover a broad range of expertise in the fields of medicine,marketing,clinical validation,AI,software development and psychology. The partnership will initially focus on Germany,one of the world's largest unified healthcare markets.
"In our efforts to give patients access to new,innovative forms of therapy,it is our aim to fully benefit from the possibilities of digitization. Alex Therapeutics is a very promising company due to its approach of combining the latest psychological findings on dealing with harmful behavior with the possibilities of artificial intelligence" says Aylin Tüzel,Country Manager Pfizer Germany,explaining the choice of cooperation partner.
"Alex DTx Platform" uses Artificial Intelligence to treat medical conditions
The partnership will utilize Alex Therapeutics' AI-powered digital therapeutics platform "Alex DTx Platform". The platform combines evidence-based psychology,primarily Cognitive Behavioural Therapy (CBT) and Acceptance and Commitment Therapy (ACT) with AI,and provides personalised standalone treatments to address unmet needs among patients worldwide.
John Drakenberg Renander,CEO of Alex Therapeutics,is excited by the opportunity to scale their novel treatments: "The collaboration with Pfizer enables us to combine our technology and expertise with one of the world's leading pharmaceutical companies and gives us unique access to an attractive healthcare market. Pfizer's unique experience of the needs of patients and doctors provides us with the opportunity to put our technology into the hands of those that need it the most."
The initial focus of the partnership is a digital therapy treating nicotine addiction via smartphone. The medical device was developed by Alex Therapeutics and adapted to the requirements of the German healthcare system together with Pfizer Germany. Pfizer is currently conducting an extensive clinical trial in Germany to further validate the medical benefits of the solution.
Germany has emerged as one of the leading countries in Digital Therapeutics
Josh Raysman,the leader of Pfizer's Digital Innovation Lab,sees in the partnership a proof-point for collaborations in digital health. "We are working around the globe to leverage innovative digital approaches to enhance patient experiences and improve health outcomes. With the recent Digital Supply Act,the expertise of Pfizer's colleagues in Germany,and the capabilities of Alex Therapeutics we have an opportunity to demonstrate the potential of patient-centric partnerships focused on transforming healthcare with digital treatments"
German-Swedish Collaboration
In January 2017,Germany and Sweden decided on a comprehensive partnership for innovation. The partnership tackles societal challenges within key areas,such as ehealth and AI,where Germany and Sweden have strong positions,and holds potential to develop the role of the EU.
"This is a great example of how innovative companies such as Alex Therapeutics in Sweden and Pfizer in Germany can come together in the fields of ehealth and AI. Together,they will provide new solutions to the benefit of patients."
Per Thöresson,Swedish Ambassador in Germany
Contact
Pfizer Deutschland GmbH
External Communications
Miriam Münch
Linkstraße 10,D-10785 Berlin
Telefon: +49 (0)30 – 55 00 55 – 51088
E-Mail: presse@pfizer.com
Website: www.pfizer.de
Twitter: www.twitter.com/pfizer_de
Youtube: www.pfizer.de/youtube
Alex Therapeutics AB
COO
Sebastian Blendow
Upplandsgatan 7,11123 Stockholm,Sweden
E-Mail: press@alextherapeutics.com
Website: www.alextherapeutics.com
About Alex Therapeutics
Alex Therapeutics is a medtech company based in Stockholm which designs and develops Software-as-a-Medical-Devices (SaMDs). With the proven "Alex DTx Platform". expertise in artificial intelligence and evidence-based psychology,Alex Therapeutics is uniquely positioned to deliver cutting-edge and reliable DTx products that demonstrably improve the health of their patients. The company has served tens of thousands of patients,has experience of clinical validation,and positive patient testimonials. For more information,visit www.alextherapeutics.comand follow us on LinkedIn.
About Pfizer: Breakthroughs That Change Patients' Lives
At Pfizer,we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality,safety and value in the discovery,development and manufacture of health care products,including innovative medicines and vaccines. Every day,Pfizer colleagues work across developed and emerging markets to advance wellness,prevention,treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies,we collaborate with health care providers,governments,and local communities to support and expand access to reliable,affordable health care around the world. For more than 170 years,we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.de. In addition,to learn more,please visit us on www.Pfizer.de and follow us on Twitter at @Pfizerand @Pfizer News,LinkedIn,YouTube and like us on Facebook at Facebook.com/Pfizer.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/21311/3494582/1526789.pdf
Press release (PDF)
